ipilimumab,nivolumab
bms
['sclc', 'nivolumab', 'ipilimumab', 'energy', 'nivo', 'nsclc']
#asco22 dr. herve lena presents results from phase iii study of nivolumab + ipilimumab vs chemo (4 cycles +/- maintenance pemetrexed) in ps 2 or elderly ( 70) pts with nsclc (energy-gfpc 06-2015 study). primary endpoint os. stratified by age, ps, histology (but not pdl1). 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him